BC Extra | Jul 3, 2019
Company News

July 3 Company Quick Takes: Dovato approved in Europe for HIV; plus Alexion, RedHill and Insys

EC approves Dovato for HIV The European Commission approved once-daily Dovato dolutegravir/lamivudine from ViiV Healthcare Ltd. (Brentford, U.K.) to treat HIV-1 infection in adults and adolescents above 12 years of age. Third approval for Ultomiris...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BC Extra | Jun 11, 2019
Company News

June 10 Company Quick Takes: Roche's Spark takeover delayed again; plus Insys, China audits, Novavax and more

More delays for Roche's Spark acquisition, plus U.K. investigation   After at least three previous delays, Roche (SIX:ROG; OTCQX:RHHBY) has extended its deadline to acquire Spark Therapeutics Inc. (NASDAQ:ONCE) to July 31 from June 14...
BC Extra | May 3, 2019
Company News

May 3 Company Quick Takes: NHS England, Acacia, Insys, Novo, AZ

NHS strikes deal aimed at eliminating HCV in England  NHS England partnered with Gilead Sciences Inc. (NASDAQ:GILD), Merck & Co. Inc. (NYSE:MRK) and AbbVie Inc. (NYSE:ABBV) to identify and treat individuals who are unaware they...
BC Extra | Apr 15, 2019
Company News

Management tracks: GW Pharmaceuticals, Aurinia

Cannabinoid company GW Pharmaceuticals plc (NASDAQ:GWPH) hired Darren Cline as chief commercial officer. He succeeds Julian Gangolli who is retiring. Cline was EVP, commercial at Seattle Genetics Inc. (NASDAQ:SGEN). Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) hired...
BC Week In Review | Jan 11, 2019
Company News

Former Insys CEO pleads guilty to opioid prescription kickbacks

Michael Babich, former president and CEO of Insys Therapeutics Inc. (NASDAQ:INSY), pleaded guilty on Jan. 9 in conspiring to bribe physicians to unnecessarily prescribe Subsys fentanyl sublingual spray and defraud insurance companies. The opioid is...
BC Extra | Oct 11, 2018
Company News

Management tracks: Former Baxalta exec joins VisionGate; Carrick names Golumbeski chair

Cancer company VisionGate Inc. (Phoenix, Ariz.) hired John Glasspool as chief operating and strategy officer, a newly created position. He was EVP and head of corporate strategy and customer operations at Baxalta Inc., which Shire...
BioCentury | Oct 6, 2018
Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
BC Week In Review | Aug 31, 2018
Clinical News

Fast Track for Insys' nasal epinephrine

Insys Therapeutics Inc. (NASDAQ:INSY) jumped $2.71 (34%) to $10.67 on Aug. 30 after it said FDA granted Fast Track designation to its epinephrine nasal spray to treat anaphylaxis. A spokesperson for Insys told BioCentury that...
BC Week In Review | Aug 10, 2018
Company News

FDA reviewers say data are lacking on TIRF drug use

FDA reviewers pointed to significant data gaps for evaluating the REMS program for transmucosal immediate-release fentanyl (TIRF) drugs at a joint advisory committee meeting Aug. 3. Participants gave "important feedback" that insufficient data exists to...
Items per page:
1 - 10 of 89
BC Extra | Jul 3, 2019
Company News

July 3 Company Quick Takes: Dovato approved in Europe for HIV; plus Alexion, RedHill and Insys

EC approves Dovato for HIV The European Commission approved once-daily Dovato dolutegravir/lamivudine from ViiV Healthcare Ltd. (Brentford, U.K.) to treat HIV-1 infection in adults and adolescents above 12 years of age. Third approval for Ultomiris...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BC Extra | Jun 11, 2019
Company News

June 10 Company Quick Takes: Roche's Spark takeover delayed again; plus Insys, China audits, Novavax and more

More delays for Roche's Spark acquisition, plus U.K. investigation   After at least three previous delays, Roche (SIX:ROG; OTCQX:RHHBY) has extended its deadline to acquire Spark Therapeutics Inc. (NASDAQ:ONCE) to July 31 from June 14...
BC Extra | May 3, 2019
Company News

May 3 Company Quick Takes: NHS England, Acacia, Insys, Novo, AZ

NHS strikes deal aimed at eliminating HCV in England  NHS England partnered with Gilead Sciences Inc. (NASDAQ:GILD), Merck & Co. Inc. (NYSE:MRK) and AbbVie Inc. (NYSE:ABBV) to identify and treat individuals who are unaware they...
BC Extra | Apr 15, 2019
Company News

Management tracks: GW Pharmaceuticals, Aurinia

Cannabinoid company GW Pharmaceuticals plc (NASDAQ:GWPH) hired Darren Cline as chief commercial officer. He succeeds Julian Gangolli who is retiring. Cline was EVP, commercial at Seattle Genetics Inc. (NASDAQ:SGEN). Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) hired...
BC Week In Review | Jan 11, 2019
Company News

Former Insys CEO pleads guilty to opioid prescription kickbacks

Michael Babich, former president and CEO of Insys Therapeutics Inc. (NASDAQ:INSY), pleaded guilty on Jan. 9 in conspiring to bribe physicians to unnecessarily prescribe Subsys fentanyl sublingual spray and defraud insurance companies. The opioid is...
BC Extra | Oct 11, 2018
Company News

Management tracks: Former Baxalta exec joins VisionGate; Carrick names Golumbeski chair

Cancer company VisionGate Inc. (Phoenix, Ariz.) hired John Glasspool as chief operating and strategy officer, a newly created position. He was EVP and head of corporate strategy and customer operations at Baxalta Inc., which Shire...
BioCentury | Oct 6, 2018
Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
BC Week In Review | Aug 31, 2018
Clinical News

Fast Track for Insys' nasal epinephrine

Insys Therapeutics Inc. (NASDAQ:INSY) jumped $2.71 (34%) to $10.67 on Aug. 30 after it said FDA granted Fast Track designation to its epinephrine nasal spray to treat anaphylaxis. A spokesperson for Insys told BioCentury that...
BC Week In Review | Aug 10, 2018
Company News

FDA reviewers say data are lacking on TIRF drug use

FDA reviewers pointed to significant data gaps for evaluating the REMS program for transmucosal immediate-release fentanyl (TIRF) drugs at a joint advisory committee meeting Aug. 3. Participants gave "important feedback" that insufficient data exists to...
Items per page:
1 - 10 of 89